



Erratum

Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). *Diabetes Care* 2014;37:2159–2167

DOI: 10.2337/dc15-er07b

Carol Wysham, Thomas Blevins,
Richard Arakaki, Gildred Colon,
Pedro Garcia, Charles Atisso,
Debra Kuhstoss, and Mark Lakshmanan

In the print version of the article cited above, a footnote was omitted with respect to antidrug antibodies (ADAs) in Table 2. Exenatide values reported in the last row in Table 2 are not treatment-emergent ADAs; they are total reported ADAs. The last three rows of Table 2 should have appeared as follows:

ADAs ^a							
Dulaglutide ADAs	4 (1.4)	2 (0.7)	12 (4.3)	2 (1.4)	5 (1.8)	3 (1.1)	14 (5.1)
Exenatide ADAs	—	—	75 (27.2)	—	—	—	58 (21.0)

^aDulaglutide ADA values are treatment emergent; exenatide ADA values are total reported ADAs.

In addition, three sentences require revision. Page 2165, RESULTS section, the sentence “Ten (1.8%) patients randomized to dulaglutide developed treatment-emergent dulaglutide ADAs at least once postbaseline during the 52-week study (Table 2)” should read, “Ten (1.8%) patients randomized to dulaglutide developed treatment-emergent dulaglutide ADAs at least once postbaseline during the 52-week study, including the follow-up period (Table 2).” Page 2165, RESULTS section, the sentence “In exenatide-treated patients at 26 weeks, 48% were noted to have treatment-emergent exenatide ADAs (Table 2) of whom one experienced an injection site reaction” should read, “In exenatide-treated patients at 52 weeks, 48% cumulatively, with 21% at 26 weeks, were noted to have exenatide ADAs (Table 2) of whom one experienced an injection site reaction.” Page 2166, CONCLUSIONS section, the sentence “The immunogenicity of dulaglutide appeared to be low, with <2% of patients developing treatment-emergent dulaglutide ADAs in contrast to a 47% incidence in patients treated with exenatide” should read, “The immunogenicity of dulaglutide appeared to be low, with <2% of patients developing treatment-emergent dulaglutide ADAs in contrast to a 48% incidence of antiexenatide antibodies in patients treated with exenatide.” The online version reflects these changes.